New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
CRISPR studies identify many promising therapeutic targets for multiple myeloma

CRISPR studies identify many promising therapeutic targets for multiple myeloma

byDana-Farber Cancer InstituteComparative analysis of CERES scores for MM preferential dependencies in MM vs other hematologic malignancies vs. solid tumors. Results are presented in a manner si
World medicine December 05,2023
CRISPR studies identify many promising therapeutic targets for multiple myeloma

CRISPR studies identify many promising therapeutic targets for multiple myeloma

byDana-Farber Cancer InstituteComparative analysis of CERES scores for MM preferential dependencies in MM vs other hematologic malignancies vs. solid tumors. Results are presented in a manner si
World medicine December 05,2023
Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

by American College of Medical Genetics and GenomicsCases illustrating CHEK2 testing in practice. CHEK2 case #2 is a 35-year-old female who was originally diagnosed at age 33 years with stage 2 breast
World medicine December 05,2023
Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

by American College of Medical Genetics and GenomicsCases illustrating CHEK2 testing in practice. CHEK2 case #2 is a 35-year-old female who was originally diagnosed at age 33 years with stage 2 breast
World medicine December 05,2023
ChatGPT shows limited ability to recommend guidelines-based cancer treatments

ChatGPT shows limited ability to recommend guidelines-based cancer treatments

byBrigham and Women's HospitalCredit: Pixabay/CC0 Public DomainFor many patients, the internet serves as a powerful tool for self-education on medical topics. With ChatGPT now at patients&#3
World medicine December 05,2023
ChatGPT shows limited ability to recommend guidelines-based cancer treatments

ChatGPT shows limited ability to recommend guidelines-based cancer treatments

byBrigham and Women's HospitalCredit: Pixabay/CC0 Public DomainFor many patients, the internet serves as a powerful tool for self-education on medical topics. With ChatGPT now at patients&#3
World medicine December 05,2023
CDK9 inhibitors: A promising combination partner in treating hematological malignancies

CDK9 inhibitors: A promising combination partner in treating hematological malignancies

by Impact Journals LLCPET scan at screening (A), 5 months (B) and 8 months on treatment (C). Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28473A new research perspective titled "
World medicine December 05,2023
CDK9 inhibitors: A promising combination partner in treating hematological malignancies

CDK9 inhibitors: A promising combination partner in treating hematological malignancies

by Impact Journals LLCPET scan at screening (A), 5 months (B) and 8 months on treatment (C). Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28473A new research perspective titled "
World medicine December 05,2023
CAR-T immune therapy attacks ovarian cancer in mice with a single dose

CAR-T immune therapy attacks ovarian cancer in mice with a single dose

by Liz Ahlberg Touchstone,University of Illinois at Urbana-ChampaignScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit:
World medicine December 05,2023
CAR-T immune therapy attacks ovarian cancer in mice with a single dose

CAR-T immune therapy attacks ovarian cancer in mice with a single dose

by Liz Ahlberg Touchstone,University of Illinois at Urbana-ChampaignScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit:
World medicine December 05,2023
CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

byBaylor College of MedicineGD2-CAR.15 NKTs expand in peripheral blood, traffic to metastatic tumor sites and induce complete remission. Credit:Nature Medicine(2023). DOI: 10.1038/s4
World medicine December 05,2023
CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

byBaylor College of MedicineGD2-CAR.15 NKTs expand in peripheral blood, traffic to metastatic tumor sites and induce complete remission. Credit:Nature Medicine(2023). DOI: 10.1038/s4
World medicine December 05,2023
What is the best lymphoma treatment after CAR T therapy fails?

What is the best lymphoma treatment after CAR T therapy fails?

by Greg Glasgow,CU Anschutz Medical CampusCredit: Pixabay/CC0 Public DomainFor 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma
World medicine December 05,2023
What is the best lymphoma treatment after CAR T therapy fails?

What is the best lymphoma treatment after CAR T therapy fails?

by Greg Glasgow,CU Anschutz Medical CampusCredit: Pixabay/CC0 Public DomainFor 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma
World medicine December 05,2023
New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

byUniversity of Maryland School of MedicineCD229 expression on CAR T cells. CD229 expression was determined on the surface of CAR T cell products at day 9 of production as well as unstimulated T
World medicine December 05,2023
New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

byUniversity of Maryland School of MedicineCD229 expression on CAR T cells. CD229 expression was determined on the surface of CAR T cell products at day 9 of production as well as unstimulated T
World medicine December 05,2023
Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

by Elana GotkineFor patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therap
World medicine December 05,2023
Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

by Elana GotkineFor patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therap
World medicine December 05,2023
Cancer may lurk in 'normal looking' skin

Cancer may lurk in 'normal looking' skin

byUniversity of QueenslandSkin mutation load reflects ultraviolet (UV) exposure. (A) Left: Mutation load of chronic ultraviolet B (UVB)–irradiated mice. Right: Spearman correlation of mutation l
World medicine December 05,2023
Cancer may lurk in 'normal looking' skin

Cancer may lurk in 'normal looking' skin

byUniversity of QueenslandSkin mutation load reflects ultraviolet (UV) exposure. (A) Left: Mutation load of chronic ultraviolet B (UVB)–irradiated mice. Right: Spearman correlation of mutation l
World medicine December 05,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com